The successful implementation of clinical genomics extends beyond laboratory accuracy to encompass how molecular information enters clinical workflows, supports decision-making, and influences patient care trajectories. Pathologists and laboratory directors must interpret complex variant classifications and communicate uncertain or incidental findings to ordering clinicians who may lack specialized genomic training. Genetic counselors serve as critical intermediaries, translating technical results into meaningful information for patients and families while addressing psychosocial implications of inherited risk. Oncologists integrate tumor profiling into treatment planning, navigating increasingly complex therapeutic landscapes where multiple biomarker-directed options may exist for a given malignancy. Primary care providers face growing responsibility for interpreting pharmacogenomic results and managing incidental findings of uncertain significance that emerge from broad genomic testing. Health system administrators must invest in electronic health record integration, decision support tools, and workforce development that enable genomic medicine at scale rather than isolated excellence. These implementation challenges create opportunities for companies developing clinical decision support platforms, variant interpretation services, and educational programs that bridge gaps between genomic capability and clinical practice. Understanding which companies address genuine implementation barriers versus merely adding complexity is central to evaluating sustainable value creation in clinical genomics.